- Home
- IMMX vs BLAC Comparison
IMMX vs BLAC Comparison
Compare IMMX & BLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- BLAC
- Stock Information
- Founded
- IMMX 2014
- BLAC 2020
- Country
- IMMX United States
- BLAC United States
- Employees
- IMMX N/A
- BLAC N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- BLAC
- Sector
- IMMX Health Care
- BLAC
- Exchange
- IMMX Nasdaq
- BLAC NYSE
- Market Cap
- IMMX 51.1M
- BLAC 44.0M
- IPO Year
- IMMX 2021
- BLAC 2023
- Fundamental
- Price
- IMMX $1.66
- BLAC $10.89
- Analyst Decision
- IMMX Strong Buy
- BLAC
- Analyst Count
- IMMX 1
- BLAC 0
- Target Price
- IMMX $7.00
- BLAC N/A
- AVG Volume (30 Days)
- IMMX 108.3K
- BLAC 502.0
- Earning Date
- IMMX 11-11-2024
- BLAC 01-01-0001
- Dividend Yield
- IMMX N/A
- BLAC N/A
- EPS Growth
- IMMX N/A
- BLAC N/A
- EPS
- IMMX N/A
- BLAC N/A
- Revenue
- IMMX N/A
- BLAC N/A
- Revenue This Year
- IMMX N/A
- BLAC N/A
- Revenue Next Year
- IMMX $200.00
- BLAC N/A
- P/E Ratio
- IMMX N/A
- BLAC N/A
- Revenue Growth
- IMMX N/A
- BLAC N/A
- 52 Week Low
- IMMX $1.26
- BLAC $10.39
- 52 Week High
- IMMX $7.75
- BLAC $11.60
- Technical
- Relative Strength Index (RSI)
- IMMX 45.76
- BLAC 61.32
- Support Level
- IMMX $1.43
- BLAC $10.80
- Resistance Level
- IMMX $1.94
- BLAC $10.87
- Average True Range (ATR)
- IMMX 0.13
- BLAC 0.00
- MACD
- IMMX -0.01
- BLAC -0.00
- Stochastic Oscillator
- IMMX 57.97
- BLAC 0.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BLAC BELLEVUE LIFE SCIENCES ACQ CORP
Bellevue Life Sciences Acquisition Corp is a blank check company.